Business Context and Reporting Period
Company: Autolus Therapeutics Plc
Filing Type: Form 6-K (Unaudited Condensed Consolidated Financial Statements)
Reporting Period: Six months ended June 30, 2020
Business Overview: Autolus is a biopharmaceutical company developing next-generation programmed T cell therapies for cancer treatment. The company is in the pre-revenue stage, funding operations primarily through equity offerings. As of June 30, 2020, the company had cash and restricted cash of $212.8 million, which management believes is sufficient to fund operations for at least twelve months.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2020 |
Six Months Ended June 30, 2019 |
|---|---|---|
| Grant Income | $631 | $2,302 |
| Total Operating Expenses | $(78,107) | $(67,362) |
| Research & Development | $(62,615) | $(48,738) |
| General & Administrative | $(16,123) | $(20,926) |
| Net Loss | $(61,918) | $(55,655) |
| Net Loss Per Share (Basic & Diluted) | $(1.22) | $(1.34) |
| Cash Used in Operating Activities | $(50,966) | $(43,730) |
| Cash Provided by Financing Activities | $74,013 | $109,405 |
| Cash and Restricted Cash (End of Period) | $212,830 | $266,877 |
| Total Assets | $310,548 | $303,533 |
| Accumulated Deficit | $(299,068) | $(237,150) |
Material Changes vs. Prior Period
- Revenue: The company generated no product revenue. Grant income decreased to $0.6 million from $2.3 million in the prior year period.
- Operating Expenses: Total operating expenses increased by approximately $10.7 million (16%) year-over-year. Research and Development (R&D) expenses rose by $13.9 million, driven by clinical development activities. General and Administrative (G&A) expenses decreased by $4.8 million.
- Net Loss: Net loss increased by $6.3 million to $61.9 million. This was partially offset by a significant increase in the income tax benefit to $10.7 million (from $6.7 million), resulting in a lower loss per share despite higher absolute losses.
- Cash Flow: Net cash used in operating activities increased by $7.2 million. However, the company raised $74.0 million in net proceeds from a public offering of 7.25 million ADSs in January 2020, compared to $109.4 million raised in the prior year period.
- Foreign Exchange: The company recorded a foreign currency translation loss of $19.5 million in comprehensive loss for the six months ended June 30, 2020, compared to $3.8 million in the prior year.
Outlook, Risks, and Management Commentary
- Liquidity and Capital Needs: Management states that cash on hand of $212.0 million is sufficient to fund operations for at least twelve months. The company expects to continue generating operating losses for the foreseeable future and will require additional capital to fund clinical trials and commercialization.
- COVID-19 Impact: The company transitioned to remote work in March 2020, with exceptions for clinical trial and manufacturing activities. Laboratories and offices began reopening in June 2020 under phased protocols. Management is monitoring the impact on clinical trial sites and supply chains but has not identified specific events requiring asset impairment or liability revision as of June 30, 2020.
- License Agreements: The company holds an exclusive license from UCL Business plc (UCLB) and Noile-Immune Biotech Inc. Future obligations include potential milestone payments and royalties upon regulatory approval and commercialization. A $0.6 million milestone payment to UCLB was accrued as probable.
- Lease Commitments: The company has significant lease liabilities ($28.2 million total) related to office and manufacturing facilities in the UK and US. In 2019, the company discontinued fit-out of a manufacturing facility, expensing $4.1 million, but determined no impairment was necessary as of June 30, 2020.
- Share-Based Compensation: Total share-based compensation expense was $11.5 million for the six months ended June 30, 2020. Unrecognized compensation expense related to unvested options and RSUs totaled approximately $27.0 million as of period end.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $212.8 million cash balance against projected burn rates, given the company's pre-revenue status and reliance on future equity financing.
- R&D Spend Trajectory: Monitor the 28% year-over-year increase in R&D expenses and its alignment with clinical trial milestones for product candidates (e.g., AUTO1).
- Foreign Exchange Exposure: Assess the impact of currency fluctuations, which contributed a $19.5 million translation loss to comprehensive loss, on future financial reporting.
- Future Milestone Liabilities: Review the potential future cash outflows associated with the UCLB license agreement, including regulatory and commercialization milestones totaling up to £104.5 million.
- Equity Dilution: Note the issuance of 7.25 million ADSs in January 2020 and the existence of approximately 6.6 million potentially dilutive securities (options and unvested shares) outstanding.